High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease (OPTINEB)

Poitiers University Hospital

Status and phase: Unknown; Phase 3

Conditions: Chronic Obstructive Pulmonary Disease; High-flow Nasal Cannula

Treatments: Drug: salbutamol

Study type: Interventional

Funder types: Other

Identifiers

NCT03449056

OPTINEB

Details and patient eligibility

About

High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns "de novo" acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied. Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Arterial pH over 7.25,
• Respiratory rate under 35 breaths/mn
• Glasgow Coma Scale equal to 15,
• indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours),
• NIV sessions spaced more than 6 hours.

Exclusion criteria

• Urgent endotracheal intubation;
• Contraindication to beta 2 adrenergic agonist;
• Another organ failure (hemodynamic and neurological instability);
• Cardioselective beta-blocker during treatment of copd exacerbation;

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

TREATMENT

Experimental group

Description:

salbutamol nebulization

Treatment:

Drug: salbutamol